AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...
XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced the completion of a...
CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT
China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...
InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...
Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical...
Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...
Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...
3SBio Partners with Thermo Fisher to Advance Cell and Gene Therapy Solutions
China-based 3SBio Inc. (HKG: 1530) announced last week a strategic partnership with US-based life sciences...
Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73
China-based Jacobio Pharma (HKG: 1167) announced the first patient dosing of a Phase I/IIa study...
Shanghai Pharmaceuticals’ MediTrust Health Files for IPO in Hong Kong Amidst AI-Powered Healthcare Payment Transformation
Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) subsidiary, Shanghai MediTrust Health Technology...
Hisun Pharmaceuticals Receives NMPA Approval for HS387 Clinical Trials in Advanced Solid Tumors
China-based Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) announced that it has received clinical trial...
China Isotope & Radiation Corporation Showcases C-14 Barium Carbonate at International Symposium
China Isotope & Radiation Corporation (CIRC; HKG: 1763) announced that it showcased its C-14 barium...
Merck KGaA Completes $3.4 Billion Acquisition of SpringWorks Therapeutics Boosting Rare Oncology Portfolio
German pharmaceutical giant Merck KGaA (ETR: MRK) has completed its USD 3.4 billion (EUR 3...
Allergan Aesthetics’ SKINVIVE by JUVÉDERM Accepted for FDA Review to Reduce Neck Lines
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that the supplemental premarket approval (sPMA) application...
Hybio and iCarbonX Enter CRDMO Service Pact and Strategic Investment to Advance Peptide Drug Pipeline
This week, China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) and iCarbonX entered into an innovative...
EnChannel Medical Acquires AcQMap Platform Assets from Acutus Medical to Strengthen Non-Contact Mapping Tech
Guangzhou-based electrophysiology platform company EnChannel Medical Ltd. is set to acquire the AcQMap High Resolution...
Jiangsu Hengrui Pharmaceuticals Partners with NSFC to Establish Private Enterprise Innovation Fund
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced an agreement with the National...
Sanofi Invests $25 Million in China’s Adagene to Advance SAFEbody Program
French pharmaceutical major Sanofi (NASDAQ: SNY) is set to make a USD 25 million investment...
NHSA Unveils Plans for 2025 National Drug List Adjustments and Commercial Insurance Drug List
This week, China’s National Healthcare Security Administration (NHSA) released two draft documents detailing a plan...